Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Unraveling Novel Mechanisms for Targeting the Intra-S-Phase Checkpoint in p53-Mutated Acute Myeloid Leukemia

Sean M. Post, Ashley G Rodriguez, Oscar Benitez, Jared Brottem, Irene Wang, Joanne Chang, Mark G. Frattini, Abhishek Maiti

Blood (2023) 142 (Supplement 1): 1423.

https://doi.org/10.1182/blood-2023-189333

Published: 2023

Journal Articles

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Jeremy S. Abramson, Aravind Ramakrishnan, Ana Alfonso Pierola, Ira Braunschweig, Guillaume Cartron, Catherine Thieblemont, Jose A. Pérez-Simón, Pere Barba, Peter A. Riedell, Carlos Solano, Thomas Gastinne, Alexandra LaCroce, Denise Thomas, Camille Poirot, Sarah Meadows, Kathryn J. Newhall, Daniel J. Lee, Mark G. Frattini, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2023-186570

Published: 2023

Journal Articles

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, Patrice Chevallier, Hongtao Liu, Gary J. Schiller, Jean-Baptiste Méar, Daniel J. DeAngelo, Kevin J Curran, Stephan Grupp, Andre Baruchel, Marie Balsat, Alexandra LaCroce, Caroline Roudet, Ana B. Korngold, Kathryn J. Newhall, Eric Laille, Daniel J. Lee, Mark G. Frattini, Richard A. Larson, Nicolas Boissel

Blood (2023) 142 (Supplement 1): 4847.

https://doi.org/10.1182/blood-2023-187252

Published: 2023

Journal Articles

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

David A. Sallman, Daniel J. DeAngelo, Naveen Pemmaraju, Shira Dinner, Saar Gill, Rebecca L. Olin, Eunice S. Wang, Marina Konopleva, Eileen Stark, Ana Korngold, Asifa Haider, Kate Backhouse, Carolyn Figliola, Daniel J. Lee, Mark G. Frattini, Carrie Brownstein, Gail J. Roboz

Blood (2022) 140 (Supplement 1): 2371–2373.

https://doi.org/10.1182/blood-2022-169928

Published: 2022

Journal Articles

Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, Gail J. Roboz, Marina Konopleva, Hongtao Liu, Gary J. Schiller, Elias J. Jabbour, Deborah Whitfield, Asifa Haider, Oleg Zernovak, Mark G. Frattini, Carrie Brownstein, Richard A. Larson

Blood (2021) 138 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2021-150779

Published: 2021

Journal Articles

Pre-Clinical Development of a Highly Efficient TALEN ® -Based Correction of the β-Globin Gene in Patient-Derived Hematopoietic Stem and Progenitor Cells (HSPCs) to Treat Sickle Cell Disease

Blood (2021) 138 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2021-153549

Published: 2021

Journal Articles

Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation

Blood (2021) 138 (Supplement 1): 1276.

https://doi.org/10.1182/blood-2021-146507

Published: 2021

Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Blood (2021) 137 (13): 1792–1803.

https://doi.org/10.1182/blood.2020007233

Published: 2021

Includes: Supplemental data

Journal Articles

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Alexander Coltoff, MD, Joseph G. Jurcic, MD, Peter Campbell, PharmD, BCOP, Daniel J. Lee, MD, Mark L Heaney, MD, Nicole Lamanna, MD, Todd L. Rosenblat, MD MS, Mark G. Frattini, MDPhD, George Vlad, PhD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-134237

Published: 2020

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

https://doi.org/10.1182/blood-2019-130362

Published: 2019

Journal Articles

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Emily F Mason, MD PhD, Olga Pozdnyakova, MD PhD, Mikhail Roshal, MD PhD, Amir T. Fathi, MD, Eytan M. Stein, MD, Aaron C. Shaver, MD PhD, Mark G. Frattini, MD, Hongfang Wang, PhD, Lei Hua, PhD, Jimmy Mu, Caroline Almon, MS, Michael Cooper, MD, Richard M. Stone, MD, Robert P. Hasserjian, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1442.

https://doi.org/10.1182/blood-2019-123845

Published: 2019

Journal Articles

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Stephane De Botton, Joseph M Brandwein, MD, Eytan M. Stein, MD, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, MD PhD, Peter Paschka, MD, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, MD, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner

Blood (2019) 134 (Supplement_1): 3893.

https://doi.org/10.1182/blood-2019-122700

Published: 2019

Journal Articles

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Kara Cicero, MD MPH, Mark L Heaney, Todd L. Rosenblat, MD MS, Nicole Lamanna, MD, Joseph G. Jurcic, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD

Blood (2019) 134 (Supplement_1): 3899.

https://doi.org/10.1182/blood-2019-130203

Published: 2019

Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD

Blood (2018) 132 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2018-99-117257

Published: 2018

Journal Articles

Direct Comparison of in-Vitro Growth of Primary Human Acute Myeloid Leukemia (AML) Cells in Stromal and Stromal-Free Conditions

Jing Chen, MD, Glorymar Ibanez-Sanchez, Paul Calder, Mark G. Frattini, MD PhD

Blood (2018) 132 (Supplement 1): 5096.

https://doi.org/10.1182/blood-2018-99-116978

Published: 2018

Journal Articles

Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance

Blood (2018) 132 (Supplement 1): 441.

https://doi.org/10.1182/blood-2018-99-116383

Published: 2018

Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Tara L Lin, MD, Carlos E Vigil, MD, Andrew Dalovisio, MD, Eunice S. Wang, MD, Moshe Yair Levy, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD, Pau Montesinos, MD PhD, Juan Miguel Miguel Bergua Burgues, Jeffrey R. Schriber, MD, Stephen Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD

Blood (2018) 132 (Supplement 1): 30.

https://doi.org/10.1182/blood-2018-99-115018

Published: 2018

Journal Articles

Immunological Correlates of Treatment with the CTLA-4 Inhibitor Ipilimumab in Patients with Refractory Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 1699.

https://doi.org/10.1182/blood.V130.Suppl_1.1699.1699

Published: 2017

Journal Articles

Stroma-Based Versus Stroma-Free Long-Term Survival and Proliferation of Primary Acute Myeloid Leukemia (AML) Cells

Jing Chen, MD, Glorymar Ibanez-Sanchez, Paul Calder, Mark G. Frattini, MD PhD

Blood (2017) 130 (Supplement 1): 5569.

https://doi.org/10.1182/blood.V130.Suppl_1.5569.5569

Published: 2017

Journal Articles

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Daniel J. Lee, MD, Todd L. Rosenblat, MD MS, Mark Lawrence Heaney, MD PhD, Joseph G. Jurcic, MD, Azra Raza, MD, Kristina Gazivoda, Katherine Harwood, Ryan Shelton, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2016) 128 (22): 2816.

https://doi.org/10.1182/blood.V128.22.2816.2816

Published: 2016

NARROW

Unraveling Novel Mechanisms for Targeting the Intra-S-Phase Checkpoint in p53-Mutated Acute Myeloid Leukemia

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Pre-Clinical Development of a Highly Efficient TALEN ® -Based Correction of the β-Globin Gene in Patient-Derived Hematopoietic Stem and Progenitor Cells (HSPCs) to Treat Sickle Cell Disease

Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Direct Comparison of in-Vitro Growth of Primary Human Acute Myeloid Leukemia (AML) Cells in Stromal and Stromal-Free Conditions

Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Immunological Correlates of Treatment with the CTLA-4 Inhibitor Ipilimumab in Patients with Refractory Myelodysplastic Syndromes (MDS)

Stroma-Based Versus Stroma-Free Long-Term Survival and Proliferation of Primary Acute Myeloid Leukemia (AML) Cells

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only